Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin

Johnson, Peter Anto; Adelglass, Jeffrey; Rankin, Bruce; Sterling, Rosalyn P.; Keating, Karen; Benson, A.; Pertel, Peter

doi:10.1111/j.1742-1241.2007.01518..x

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many clinical studies have shown the efficacy of moxifloxacin in the treatment of acute maxillary sinusitis (Arrieta et al, 2007;Gehanno et al, 2003;Johnson et al, 2008;Rakkar et al, 2001;Zhou et al, 2010). In our opinion, the microbiological results of this study suggest that clinical trials should be designed to investigate the clinical usefulness of moxifloxacin in the treatment of chronic maxillary sinusitis also.…”

Section: Discussionmentioning

confidence: 91%

Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis

Puglisi

Privitera

Maiolino

et al. 2011

Journal of Medical Microbiology

View full text Add to dashboard Cite

The main objectives of this study were to estimate the frequency of chronic maxillary sinusitis of dental origin, and to evaluate the microbiology of odontogenic and non-odontogenic chronic maxillary sinusitis. Aspirates from 59 patients with chronic maxillary sinusitis (47 non-odontogenic, 12 odontogenic), collected during a 3-year period, were microbiologically processed for aerobic and anaerobic bacteria. Moreover, antimicrobial susceptibility was evaluated in the isolated bacteria. In this study, 20 % of chronic maxillary sinusitis cases were associated with a dental origin, and sinus lift procedures were the main aetiological factor. Our microbiological findings showed that all specimens from chronic maxillary sinusitis were polymicrobial. Sixty aerobes and 75 anaerobes were recovered from the 47 cases of non-odontogenic sinusitis (2.9 bacteria per specimen); 15 aerobes and 25 anaerobes were isolated from the 12 patients with odontogenic sinusitis (3.3 bacteria per specimen). The predominant aerobes were Staphylococcus aureus (27) and Streptococcus pneumoniae (16), while the more frequent anaerobes were Peptostreptococcus species (31) and Prevotella species (30). Haemophilus influenzae and Moraxella catarrhalis were absent in sinusitis associated with a dental origin. Overall, 22 % of Staphylococcus aureus isolates were oxacillin-resistant, and 75 % of Streptococcus pneumoniae isolates were penicillin-resistant and/or erythromycin-resistant; 21 % of anaerobic Gram-positive bacteria were penicillin-resistant, and 44 % of anaerobic Gram-negative bacteria were blactamase-positive. Vancomycin and quinopristin-dalfopristin had the highest in vitro activity against Staphylococcus aureus and Streptococcus species, respectively; amoxicillin-clavulanate and cefotaxime showed the highest in vitro activity against aerobic Gram-negative bacteria; and moxifloxacin, metronidazole and clindamycin were the most active against anaerobic bacteria.

show abstract

Section: Discussionmentioning

confidence: 91%

Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis

Puglisi

Privitera

Maiolino

et al. 2011

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that moxifloxacin treatment of acute bacterial rhinosinusitis produces rapid symptom improvement with good tolerability [25], [26], and is at least effective as comparator antibiotics [32]–[35]. Numerous variables may affect the relevance of the results from randomised controlled trials to everyday clinical practice.…”

Section: Discussionmentioning

confidence: 99%

“…The pharmacokinetic and antibacterial characteristics of moxifloxacin support its use in acute bacterial rhinosinusitis [22], [24] and previous studies have shown that treatment with moxifloxacin rapidly improves the signs and symptoms of affected patients [25], [26]. According to several clinical guidelines, this respiratory fluoroquinolone is an appropriate choice of antibiotic in selected cases, such as those with more severe disease, those with a history of β-lactam allergy, where first-line antibiotic treatment has failed, where resistance to first-line antibiotics is suspected or in patients for whom the consequences of treatment failure could be serious [9], [10], [27].…”

Section: Introductionmentioning

confidence: 87%

Characterisation of Patients Receiving Moxifloxacin for Acute Bacterial Rhinosinusitis in Clinical Practice: Results from an International, Observational Cohort Study

et al. 2013

View full text Add to dashboard Cite

We conducted a prospective, non-controlled, multi-centre Phase IV observational cohort study of patients with acute bacterial rhinosinusitis who were treated with moxifloxacin in clinical practice in 19 countries in Asia Pacific, Europe and the Middle East. With the data collected we evaluated the presentation and course of the current disease episode, particularly in terms of the principal clinical signs and symptoms of acute rhinosinusitis and diagnostic procedures. A final assessment of moxifloxacin therapy was made to evaluate the impact of the sinusitis episode on activities of daily life and on sleep disturbance, and to evaluate the clinical outcome of treatment. A total of 7,090 patients were enrolled, of whom 3909 (57.6%) were included in the valid for clinical outcome and safety population. Regional differences were observed in the main symptoms of acute rhinosinusitis and, according to several characteristics, disease episodes appeared to be more severe in patients in Europe than in the Asia Pacific or Middle East regions. The sinusitis episode impacted on daily living for mean (SD) periods of 3.6 (3.2), 4.6 (3.9) and 3.1 (3.0) days and disturbed sleep for 3.6 (3.2), 4.6 (3.9) and 3.1 (3.0) nights in the Asia Pacific, Europe and Middle East regions, respectively. With moxifloxacin treatment, the mean (SD) time to improvement of symptoms was 3.0 (1.5), 3.4 (1.6) and 3.2 (1.5) days, and the time to resolution of symptoms was 4.8 (2.6) days, 5.7 (2.4) days and 5.5 (2.5) days, in the Asia Pacific, Europe and Middle East regions, respectively. In conclusion, acute rhinosinusitis remains a substantial health burden with significant impact on patients’ quality of life, and there are differences between global regions in the clinical presentation, diagnosis and clinical course of disease episodes. Moxifloxacin was an effective and well-tolerated treatment option in the overall population. Registration: ClinicalTrials.gov Identifier: NCT00930488

show abstract

The prevalence of bacterial infection in acute rhinosinusitis: A Systematic review and meta‐analysis

et al. 2014

View full text Add to dashboard Cite

Objective-To systematically assess the prevalence of bacterial infection in adults with acute rhinosinusitis (ARS) Data Sources-PubMed and CINAHL databasesReview Methods-Electronic databases were systematically searched for relevant studies published up to June 2012.Results-29 articles, evaluating a total of 9,595 patients with a clinical diagnosis of ARS, were included in the study. 14 (48%) studies required radiographic confirmation of sinusitis, 1 (3%) required evidence of purulence, 10 (35%) required both for inclusion in the study population, and 4 (14%) required neither. The random effects model estimate of prevalence of bacterial growth on all cultures was 53.7% (CI 48.4%-59.0%), ranging from 52.5% (CI 46.7%-58.3%) in studies requiring radiographic confirmation of sinusitis to 61.1% (CI 54.0%-68.1%) in studies requiring neither radiographic evidence nor purulence on exam. Studies which obtained cultures from antral swab had a prevalence of bacterial growth of 61.0% (CI 54.7%-67.2%), while those utilizing endoscopic meatal sampling had a prevalence of 32.9% (CI 19.0%-46.8%).Conclusion-Few studies evaluate the recovery of bacteria via culture in adults with a diagnosis of ABRS or ARS based on clinical criteria alone. With radiographic and/or endoscopic confirmation, antral puncture and endoscopically guided cultures produce positive bacterial cultures in approximately half of patients. Opportunities exist to improve diagnostic accuracy for bacterial infection in ARS.

show abstract

Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin

Cited by 3 publications

References 14 publications

Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis

Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis

Characterisation of Patients Receiving Moxifloxacin for Acute Bacterial Rhinosinusitis in Clinical Practice: Results from an International, Observational Cohort Study

The prevalence of bacterial infection in acute rhinosinusitis: A Systematic review and meta‐analysis

Contact Info

Product

Resources

About